Cardiorenal syndrome in urological practice


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A lecture on the pathogenesis and treatment of cardiorenal syndrome, which is a combination of various variants of renal and heart failure, is presented in the article. Currently, there are five types of this syndrome. All of them are discussed in detail from the view of relevance for urological practice.

In patients of the urological profile, II type, to a lesser extent III and V types of cardiorenal syndrome are most common. Moreover, type II, which is the simultaneous coexistence of chronic heart failure and chronic renal failure due to different (unrelated causal relationships) conditions, can significantly influence on the choice of surgical tactics. This question requires further research.

Type III of cardiorenal syndrome, which is a cardiac complication of a prolonged acute phase of acute renal failure, in most cases can be prevented through drug treatment and timely renal replacement therapy.

Type V cardiorenal syndrome, which represents a combined damage to the heart and kidneys within the same condition, apparently, occurs in urological practice in the most severe patients with metabolic syndrome, which allows to combine uric acid stones and other variants of gouty nephropathy into one nosology, naturally leading to progressive renal failure, ischemic heart disease and chronic heart failure.

In the section on treatment tactics, it is mentioned that there are no standard approaches to the treatment of cardiorenal syndrome in the literature. The restrictions in the choice and dosing regimen of cardiotropic drugs due to renal failure are considered in detail. The importance of timely hemodialysis is especially emphasized.

In conclusion, the authors suggest that the development of cardiorenal syndrome is due to the effect of potentiation with a significantly higher rate of progression of both renal and heart failure compared to isolated forms of both conditions.

全文:

受限制的访问

作者简介

S. Yarovoy

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation; GBUZ “City clinical hospital named after D.D. Pletnev" of the Health Department c. Moscow

Email: yarovoy.sk@yandex.ru
ORCID iD: 0000-0003-4543-1480

Ph.D., MD, professor, clinical pharmacologist

俄罗斯联邦, Moscow; Moscow

R. Royuk

FGBU «Burdenko GVKG», Ministry of Defense of the Russian Federation

编辑信件的主要联系方式.
Email: royuk@mail.ru
ORCID iD: 0000-0002-8335-030X

Ph.D., chief of the Department of Urology No1

俄罗斯联邦, Moscow

参考

  1. Mareev V.Yu., Fomin I.V., Ageev F.T. et al. Clinical recommendations of the OSSN – RKO – REPAIR. Heart failure: chronic (CHF) and acute decompensated (CHF). Diagnosis, prevention and treatment. Cardiologiia. 2018;58(6S):8-158. https://doi.org/10.18087/cardio.2475.
  2. Barbuk O.A. Cardiorenal syndrome: the main problems of diagnosis and treatment. Medical news. 2018;3:60–65.
  3. Reznik E.V., Nikitin I.G. Cardiorenalsyndrome in patients withchronic heart failure as a stage of the cardiorenal continuum (part I): Definition, classification, pathogenesis, diagnosis,epidemiology. The Russian Archives of Internal Medicine. 2019;9(1):5–22. [In Russian]. doi: 10.20514/2226-6704-2019-9-1-5-22.
  4. Royuk R.R., Yarovoy S.K. Chronic kidney disease in patients with recurrent nephrolithiasis and concomitant damage to the cardiovascular system. Bulletin of Urology. 2021;9(3):52–61.
  5. Reznik E.V., Gendlin G.E., Guschina V.M. Chronic kidney disease in patients with chronic heart failure (Literature review). Nephrology and dialysis. 2010;12(1):13–24.
  6. Kobalava Zh.D., Villevalde S.V., Efremovtseva M.A., Moiseev V.S. Cardiorenal relationships: modern concepts of cardiovascular therapy and prevention. 2010;9(4).
  7. Iskenderov B.G. Cardiorenal syndrome in cardiac patients Monograph. Penza. 2014. 180 s.
  8. Rameev V.V., Kozlovskaya L.V., Rameeva A.S., Tao P.P., Moiseev S.V. Features of evolution and prognostic significance of heart damage in patients with systemic al-amyloidosis. Clinical pharmacology and therapy. 2019;28(2):49–56.
  9. Prosyannikov M.Yu., Anokhin N.V., Golovanov S.A., Kirpatovsky V.I., Sivkov A.V., Konstantinova O.V., Ivanov K.V., Apolikhin O.I. Urolithiasis and cardiovascular diseases: only a statistical relationship or a common pathogenetic mechanisms? Experimental and clinical urology. 2018;3:34–41.
  10. Chronic kidney disease. Recommendations of the Scientific Society of Nephrologists of Russia. 2021. 233 c.
  11. Kobalava J., Villevalde S., Efremovtseva M., Tyukhmenev E., Klimenko A. Cardiorenal syndromes: classification, pathophysiological mechanisms, principles of diagnosis. Doctor. 2011;5:2–6.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2023
##common.cookie##